Follow the money.
Hydroxycholorquine costs about $20 for one month’s supply. It is a generic drug manufactured by several companies. It has been approved and in use since 1955 for malaria and other diseases. It is unlikely that drug companies will pay for clinical trials in view of limited profit potential.
Remdesivir is a proprietary experimental drug developed by one major medical company, Gilead Science. It has not been approved for use at all, but is being clinically tested, apparently sponsored by Gilead Science. Estimated cost for one month’s supply is $1,000. There is a high profit potential if this drug is ultimately approved.
Is it any wonder that the drug industry is trying to slow the use of Hydroxycholoroquine to maintain a market for
remdesivir after it finishes clinical trials?
The FDA has long had a symbiotic relationship with the drug industry, which some might view as incestuous, or worse. It is possible that the FDA is complicit in delaying use of hydroxychloroquine to allow a window of opportunity for the profit from Remdesivir.
[Remdesivir is a proprietary experimental drug developed by one major medical company, Gilead Science. It has not been approved for use at all, but is being clinically tested, apparently sponsored by Gilead Science. Estimated cost for one month’s supply is $1,000. There is a high profit potential if this drug is ultimately approved.]